Showing results (91-100 of 191) with videos related to
Sort By:
Pageof 20
Journal of Pharmaceutical and Biomedical Analysis|September 8, 2017
LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasmaJulia Matsumoto, Brian F Kiesel, Robert A Parise, et al.Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 25, 2007
Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasmaRobert A Parise, Jan H Beumer, Cyrous O Kangani, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2014
ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapyFan Lin, Mark C de Gooijer, Eloy Moreno Roig, et al.European Journal of Cancer (Oxford, England : 1990)|March 21, 2024
Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendationsDaniel L Hertz, Markus Joerger, Yung-Jue Bang, et al.British Journal of Clinical Pharmacology|September 11, 2009
Effect of a proton pump inhibitor on the pharmacokinetics of imatinibMerrill J Egorin, Dhvani D Shah, Susan M Christner, et al.Sarcoma|February 7, 2022
ALDH1A1 Gene Expression and Cellular Copper Levels between Low and Highly Metastatic Osteosarcoma Provide a Case for Novel Repurposing with Disulfiram and CopperJonathan B Mandell, Nerone Douglas, Vrutika Ukani, et al.Science Translational Medicine|February 14, 2018
Targeting p53-dependent stem cell loss for intestinal chemoprotectionBrian J Leibowitz, Liheng Yang, Liang Wei, et al.Cancer Chemotherapy and Pharmacology|February 15, 2020
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-upBhavana Pothuri, Allison L Brodsky, Joseph A Sparano, et al.Cancer Chemotherapy and Pharmacology|November 17, 2007
Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in miceJan H Beumer, Julie L Eiseman, Robert A Parise, et al.Cancer Chemotherapy and Pharmacology|September 1, 2015
Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humansJulianne L Holleran, Jan H Beumer, David L McCormick, et al.Pageof 20